Board of Directors

As President and Chief Executive Officer, Suzanne Gill leads Genome BC in applying the power of genomics in ways that better the lives of all British Columbians. Suzanne has been at the forefront of catalyzing sustainable, public-private partnerships across the life sciences ecosystem for more than 20 years. She provides a wealth of experience in the Canadian innovation environment, including economic development and stakeholder relations, and in helping to shape and implement strategy for organizations at the nexus of research, innovation and commercialization. Suzanne is passionate about the important work of integrating genomics into society by supporting responsible research and innovation and fostering an understanding and appreciation of the life sciences, helping BC rise to the challenges of the 21st century. Working with our partners, Suzanne’s focus is on building upon Genome BC’s successes in precision health, natural resources and education while growing BC’s thriving life sciences research and innovation ecosystem. Genomics has proven to be an important tool in the diagnosis and treatment of cancer, rare diseases and the prevention of adverse drug reactions. Genomics is also providing new and transformative ways to address BC’s environmental challenges, such as determining which plants and trees will be better able to adapt to new environmental conditions as well as identifying and managing invasive pests and disease-causing pathogens that pose threats not only to forests but also many fruit crops. Previously, Suzanne was a founding executive as the Vice President, Government Relations and Public Affairs with the Digital Supercluster (2018-2022), an industry-led organization that aims to accelerate economic growth and position Canada for global leadership in transformative digital technologies. In addition to fostering an essential relationship between industry, academia and government, she also led the development and launch of Digital Supercluster’s inaugural Capacity Building Pilot Program aimed at connecting employers to job ready digital talent. Prior to joining the Digital Supercluster, Suzanne was at Genome BC for over a decade and last held the role of Vice President, Corporate Development, responsible for corporate strategy, corporate performance management and government relations. She moved to BC following her work at the Ontario “Genomics empowers us to take control of our health, better manage our resources and keep our planet healthy. Imagine the opportunities – not yet foreseen – for future generations.” 08/2022 Genomics Institute as part of the start up team and was responsible for oversight of a $300 million research portfolio at the time when Canada was making its first large scale investments in research in the sector. Suzanne holds an MSc degree from the University of British Columbia and an MBA from the Schulich School of Business at York University in Toronto. She has been on the Board of Directors of Innovate BC since 2018.

David is a software entrepreneur who co-founded Thrive Health, a software company with a mission to improve the delivery of healthcare in Canada and beyond by empowering patients to be more informed and engaged in their journeys through specialist care.

An important element of Thrive Health’s focus is measuring and enhancing the wellbeing of patients and caregivers, leading to improved levels of physical and mental health. Thrive Health is the official developer of the B.C. and Canada COVID-19 apps, which have provided over 10 million risk assessments to Canadians during the pandemic.

Bev is a health research system leader with experience in practice
and academia and a commitment to their integration. She has more
than two decades of experience in the funding, production and use
of research evidence to improve health.

Working in the field of health and risk communication, Bev
championed stakeholder involvement and sees it as key to bringing
evidence into practice. Her doctoral degree focused on knowledge
translation: the use of research evidence to improve health and
health care. Her academic studies fueled her passion for “evidence
on evidence use” and she continues to contribute to this body of
knowledge, while learning from and applying it.

Bev chairs and sits on various research advisory groups across Canada and internationally, serves as an associate editor at Implementation Science Communications and represents her organization in the National Alliance of Provincial Health Research Organizations. She is an adjunct professor at SFU’s Faculty of Health Sciences and UBC’s School of Population and
Public Health, and holds a Chartered Director designation from the Degroote School of Business Directors College at McMaster University.

Bev is an advisor to funders interested in embracing their role as change agents to ensure citizens get maximum benefit from research investments. She publishes on and speaks about the importance of research systems, and the need for all stakeholder groups to play their part in the generation and use of knowledge to improve health and health care. In all this work, her intent is to be respectfully – but insistently – provocative.

As CEO of Michael Smith Health Research BC, Bev feels privileged to work with an outstanding Board, leadership team and staff group, and is committed to bringing evidence to her organization’s own practices towards strengthening British Columbia’s health research system. Bev was previously the CEO of Michael Smith Foundation for Health Research and has held a number of management positions in non-profit agencies. She received her MA and PhD from SFU’s School of Communication. Her research interests are knowledge translation, discourse analysis, health and risk communication, and public involvement in health research.

Wendy Hurlburt, a passionate global executive with more than 25 years of experience in the Life Sciences and Technology sectors, is the President & CEO of Life Sciences BC.  Wendy has held leadership positions in Johnson & Johnson, the Heart and Stroke Foundation of Ontario, and Lexmark International where she provided strategic leadership across Finance, Business Development, Operations, IT, Privacy, Compliance, Regulatory, Quality and Risk Management.  Her global experience includes leadership roles across Canada, the United States, Europe and South Asia.

Wendy has a BA in Finance & Economics from Western University Ontario, an MBA from Queen’s University, a Certificate in Strategic Leadership from the Sauder School of Executive Education and is a certified Privacy Professional (CIPP).  Wendy serves on the Clinical Trials BC Advisory Board, the External Advisory Committee of the Centre for Health Evaluation and Outcomes Science and the Greater Vancouver Board of Trade’s Government, Budget and Finance Committee.  Previously Wendy served on the Board of the Centre for Research and Drug Discovery (adMare BioInnovations) and chaired CDRD’s Finance & Audit Committee, co-Chaired of the International Association of Privacy Professionals Vancouver Chapter and was on the GVBOT Women’s Leadership Council, most recently serving as the WLC Policy Chair.

Dr. Lana Janes is a biopharmaceutical industry veteran with over 20 years of pharmaceutical development experience that spans the full life cycle of therapeutic product development. She is currently a Venture Partner at adMare BioInnovations and Interim Chief Executive Officer at Abdera Therapeutics.

Before joining adMare, Lana served as Senior Vice President, Intellectual Property and Technology Development and Chief Patent Officer at QLT Inc. where, for 12 years, she oversaw all aspects of global R&D and IP strategy for the company’s commercial, clinical and pre-clinical stage therapeutic programs. She has also served as COO of Retinagenix Therapeutics, a Seattle-based privately held ophthalmology company focused on rare diseases of the retina. Earlier in her career, Lana worked as a registered Canadian and US patent agent in the Toronto office of Ogilvy Renault LLP (now Norton Rose Fulbright) and at F. Hoffman-La Roche in Basel, Switzerland, where her practice focused on the strategic IP and regulatory protection for numerous therapeutic and medical device products. Lana sits on the Boards of Directors for several entrepreneurial start-up bio-techs in Vancouver, and is an associate at Creative Destruction Labs in Vancouver, providing her with valuable experience and insight in strategically and cost-effectively advancing pre-IND stage and semi-virtual companies. Lana received her AB in Chemistry with honors from Harvard University and her Ph.D. in organic chemistry from McGill University, where she also conducted post-doctoral work in the field of antiviral therapeutics. She also worked for several years as a synthetic organic chemist in the chemical and food industries in the US and UK.

Dr. David Llewellyn is Chief Strategy Officer at STEMCELL Technologies, Canada’s largest biotechnology company. David is a champion of STEMCELL’s mandate to advance science, which he supports at the executive level by ensuring the company is well positioned for long term growth and profitability.

David started his career at STEMCELL in 2006 as a Business Development Officer. Today he oversees the company’s Commercial Operations, Marketing Department, Pricing, Project Management Office, eCommerce Division, Services Division and several of its Product Teams.

David has a BSc in Chemistry from the University of Northern British Columbia, a PhD in Organic Chemistry from McGill University and an MBA in Strategic Management from the University of British Columbia.

Mr. Martin is currently Chief Operating Officer and Head of Global Business Development at Aurinia Pharmaceuticals Inc. He was formerly CEO, director and co-founder of the privately held Aurinia Pharmaceuticals Inc. which was acquired in 2013 by the former Isotechnika Pharma Inc. In his current role with Aurinia, Mr. Martin is responsible for managing company functions such as corporate and business development, alliance management, and the company’s intellectual property portfolio. Mr. Martin is a biotech/pharmaceutical executive with over 20 years of global industry experience and offers a solid mix of strategic planning, marketing, commercial operations, business development, licensing and people management skills.

Mr. Martin joined Aurinia from Vifor Pharma where he held the position of Director, Global Business Development & Licensing. Prior to Vifor, Mr. Martin was a key member of the business development team that saw Aspreva sold to Galenica for $915M. Upon joining Aspreva in 2004, Mr. Martin initiated the strategic launch planning process for CellCept® in “less-common” autoimmune diseases. These included such indications as Pemphigus Vulgaris, Myasthenia Gravis, and Lupus Nephritis. Prior thereto, Mr. Martin held a variety of progressively senior commercial positions at Schering-Plough. Most recently, Mr. Martin has spent time in Europe where he was responsible for the Rheumatology business unit for Remicade® in France. There, Mr. Martin had full profit and loss responsibilities and had direct responsibility for the sales team, the marketing team and the infusion access team. In addition, while at Schering-Plough, Mr. Martin was the brand manager responsible for the Canadian launch of Remicade (infliximab), which ultimately became the most successful product launch in Canadian history. Mr. Martin started his career in the industry in the sales organization of Schering-Plough where he received multiple achievement awards. Mr. Martin is also a member of the Board of Directors of Zucara Therapeutics based out of Toronto Canada.

Dr. David Poon is a life sciences executive with over 15 years of experience in corporate development and translating platform technologies into clinical therapeutic candidates.

David served as the Chief Business Officer at Gandeeva Therapeutics and as Vice President, Business Development and Alliance Management at Zymeworks, where he was instrumental in establishing key therapeutic program and platform partnerships with multinational pharmaceutical companies totaling over USD$10 billion. In addition, David made foundational scientific contributions to the development of the Azymetric™ and EFECT™ therapeutic platforms at Zymeworks.

David serves on the Board of Directors for BioCanRx, Canada’s Immunotherapy Network and advises several Vancouver-based biotechnology start-ups on financing, partnering, and scientific strategies.

David obtained his B.Sc. in Biology and Chemistry, and his Ph.D. in Chemistry at the University of British Columbia.

Scott holds a degree in Engineering Physics from the University of British Columbia. Prior to starting StarFish, he worked in diverse areas such as lithium battery development and manufacturing, UV spectroscopy instrumentation and hi-fi audio speakers. Under his leadership, StarFish has grown into a diverse professional organization with clients around the world and 100% focus on medical devices. Scott is a Fellow of The Canadian Academy of Engineering, 2017 recipient of the VIATEC Technology Champion award, and volunteers with Junior Achievement, Entrepreneurs Organization, UBC and Life Sciences BC. He is an EY Entrepreneur Of The Year, & 2017 Pacific Awards finalist.

Dr. Peter Zandstra focuses his work on the progression of regenerative medicine and immunotherapy. His education includes a BEng in Chemical Engineering from McGill University, a PhD in Chemical Engineering and Biotechnology from the University of British Columbia, and a Post-Doctoral Fellowship in Bioengineering from MIT.

Dr. Zandstra’s research, which incorporates engineering design principles, computational modeling, and stem cell biology, is geared towards understanding cell fate control mechanisms and developing new therapeutic strategies for diseases such as cancer and autoimmunity. His lab has produced 172 publications, garnered nearly 22,000 citations, and developed commercially applicable technologies for cell and gene therapies.

Recognized with over 30 awards, including as a Member of the Order of Canada, Dr. Zandstra’s influence is seen in his students and post-doctoral fellows who have achieved success in various sectors. Beyond his academic contributions, he co-founded the Centre for Commercialization of Regenerative Medicine (CCRM), Medicine by Design (MbD), and helped establish UBC’s School of Biomedical Engineering, demonstrating his commitment to interdisciplinary research and promoting Canadian Science and Engineering globally.

Joseph Garcia’s practice focuses on corporate finance and mergers and acquisitions. He advises public and private companies, investment dealers, venture capital and private equity funds, and acts as independent counsel to boards of directors. Joe has extensive experience advising on all types of M&A and corporate finance transactions, including public and private equity and debt financing, take-over and issuer bids, share and asset acquisitions and divestitures, and regulatory and stock exchange compliance work.

Prior to his career in law, Joe worked in corporate finance with a national investment bank and in clinical research with a multinational pharmaceutical company. Joe has lectured extensively on corporate governance and advanced securities law topics. He chaired The Continuing Legal Education Society of British Columbia corporate governance courses in 2011 and 2013, and participated in the advanced securities law courses in 2007, 2008, 2009, 2011, 2013 and 2014. Joe has been a director and corporate secretary of LifeSciences BC for more than 12 years and is a member of its Finance Committee. He is also a director of Genome British Columbia and chair of its Audit Committee, and a member of the BIOTECanada Legal Affairs advisory board.

Roger Kuypers has over 20 years’ experience as a lawyer, director and investor in the life sciences sector. His experience includes working in the biotech, medical device, diagnostics and functional foods fields. Roger has worked with start-up companies, large pharmaceutical companies, universities, centers of excellence and health authorities. Roger provides legal services in respect of a broad scope of life sciences activities, including pre-clinical and clinical research, licensing, finance and intellectual property.

On the business side, Roger has served and continues to serve on a number of corporate boards of biotech and medical device companies. On the biotech side, he served over 10 years as a director of KMT Hepatech Inc., which provides compound and vaccine testing services using its proprietary chimeric animal model. He also served as a Chairman of a local reagent and biotech company, helping to launch its translational research facilities in India. He currently serves on the boards of two BC medical device companies.

Roger also brings a broad geographic perspective to the table, being called to the British Columbia and Alberta bars. Roger practiced with Dentons in Edmonton for five years before returning to Vancouver, during which he worked closely with the Alberta life sciences community. He established the clinical trial agreement review and negotiation system for the Northern Alberta Clinical Trials and Research Centre at the University of Alberta. Roger has also acted for foreign clients, including Takeda Pharmaceutical Company of Japan.

On the community side, Roger has served as a director of BC Medtech (prior to its merger with Lifesciences BC) and the BC Clinical Research Infrastructure Network (BCCRIN). He has hosted the Speaker Series of the Clinical Research Professionals of BC for the last 17 years and is a regular presenter on legal issues in clinical research.

Hector MacKay-Dunn has over 25 years of practice experience in a broad range of industry sectors, advising on corporate and general matters, complex domestic and cross-border public and private securities offerings, mergers and acquisitions, tender offers and international partnering and licensing transactions. He provides general and strategic advice to both senior and emerging public companies as well as early to later stage private companies, investment banks, and investors in public and private domestic and cross border equity and debt financing, mergers, tender offers, corporate reorganizations, and advises boards of directors and independent board committees on corporate governance. Hector is recognized by Lexpert, the most respected legal publication in Canada, as being among the Top 100 Canada/US Cross-Border Corporate Lawyers in Canada. He has consistently been named among The Leading 500 Lawyers in Canada, and is recognized among Canada’s leading lawyers in mergers & acquisitions, technology and biotechnology. Hector has received the “AV Preeminent 5.0 out of 5″ legal ability rating from Martindale-Hubbell, an authoritative and global source for identifying leading lawyers and law firms. Hector has advised clients in a variety of commercial industries, including semi-conductor, software, web-based and e-businesses, pharmaceuticals and biotechnology, independent power production, medical equipment and devices, mining, manufacturing, transportation, and fitness services.